This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 Stocks Under $10 Making Big Moves

Array BioPharma

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Array BioPharma (ARRY - Get Report) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. This stock is trading up 5.4% at $3.68 in recent trading.

Today's Range: $3.49-$3.80

52-Week Range: $1.58-$3.53

Volume: 1.13 million

Three-Month Average Volume: 868,835

Shares of ARRY are ripping higher today after the company announced encouraging selumetinib results for phase II trials in ovarian cancer. Selumetinib was invented by Array and licensed to AstraZeneca.

From a technical perspective, ARRY is continuing a breakout pattern today now that the stock is comfortably above its recent breakout levels of $3.27 to $3.33. Volume so far is tracking in very strong and well above its average action of 868,835 shares.

Traders should now watch for ARRY to close above its next major overhead resistance level of $3.60. If we get that close today, then look for ARRY to uptrend toward $4 to $4.25 or possibly higher in the near future. Traders should consider long biased traders as long as ARRY is trending above $3.60 with strong upside volume flows.

Array shows up on a list of 7 Cancer Drug Stocks to Know Right Now.

2 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
OCZ $0.00 0.00%
SCEI $0.27 0.00%
ARRY $7.40 0.00%
OMN $8.25 0.00%
VRNG $0.69 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs